Price (delayed)
$2.75
Market cap
$51.43M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$8.27
Enterprise value
-$50.03M
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The
There are no recent dividends present for KLRS.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.